Related Experiment Video
Updated: Mar 8, 2026

Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma
Published on: February 22, 2015
Functionally distinct ALK and ROS1 fusions detected in infant-type hemispheric gliomas converge on STAT3 and SHP2
Andreas Postlmayr1, Astrid Sanchez Bergman1, Jacob Torrejon Diaz2
1Translational Brain Tumor Research, Division of Oncology and Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland.
Abstract:
ALK and ROS1 fusions are key drivers of infant-type hemispheric gliomas (IHG). With diverse gene partners, the impact of ALK and ROS1 oncoprotein heterogeneity on glioma biology remains unknown. We developed an integrative phospho-proteomic and transcriptomic approach to discover biological functions regulated by five IHG-associated fusions: CCDC88A::ALK, PPP1CB::ALK, GOPC::ROS1, CLIP1::ROS1, and KIF21A::ROS1. Here, we report fusion-specific oncogenic functions conferred by the 5' gene partner, including increased cell motility driven by microtubule-interacting fusions CCDC88A::ALK and CLIP1::ROS1. All studied fusions converge on STAT3 activation. Using affinity purification mass spectrometry, we identified SHP2 in direct interaction with all three ROS1 oncoproteins but with none of the ALK oncoproteins, which in turn interact with SHC1/SHC3. ROS1 fusions phosphorylate SHP2 to a greater extent than ALK fusions, and analyses of downstream pathways suggest MAPK-independent, non-canonical SHP2-driven functions. Our findings reveal both common and fusion-specific dependencies, offering opportunities to optimize therapeutic strategies for pediatric gliomas.
Insights
ALK and ROS1 fusions drive infant-type hemispheric gliomas (IHG). This study reveals fusion-specific functions and STAT3 activation, identifying SHP2 interactions with ROS1 fusions for potential pediatric glioma therapies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- ALK and ROS1 fusions are oncogenic drivers in infant-type hemispheric gliomas (IHG).
- The heterogeneity of ALK and ROS1 fusion partners and their impact on glioma biology are not well understood.
Purpose of the Study:
- To investigate the biological functions and oncogenic activities conferred by specific ALK and ROS1 fusion variants in IHG.
- To identify common and fusion-specific molecular dependencies for therapeutic targeting.
Main Methods:
- Integrative phospho-proteomic and transcriptomic analysis of five IHG-associated fusions (CCDC88A::ALK, PPP1CB::ALK, GOPC::ROS1, CLIP1::ROS1, KIF21A::ROS1).
- Affinity purification mass spectrometry to identify protein-protein interactions.
- Downstream pathway analysis.
Main Results:
- Fusion-specific oncogenic functions were identified, including increased cell motility associated with microtubule-interacting fusions (CCDC88A::ALK, CLIP1::ROS1).
- All studied fusions converge on STAT3 activation.
- SHP2 directly interacts with ROS1 fusions but not ALK fusions; ALK fusions interact with SHC1/SHC3. ROS1 fusions lead to greater SHP2 phosphorylation, suggesting MAPK-independent functions.
Conclusions:
- The 5' gene partner significantly influences the oncogenic functions of ALK and ROS1 fusions in IHG.
- Convergent STAT3 activation and distinct SHP2/SHC interactions highlight fusion-specific dependencies.
- These findings offer insights for developing targeted therapies for pediatric gliomas.
More Related Videos
10:13Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice
Published on: August 12, 2014
09:43Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
Published on: January 14, 2014